Georges Vassaux

Has grant

Université Côte d'Azur
Country flagFrance

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Recent Grants

Grant: Close

Elaboration d’un test in vitro d’évaluation de composés carcinogènes pour l’industrie cosmétique

Open Date: 2018-10-01

Close Date: 2021-09-01

Grant: Close

Evaluation d'une formulation permettant la transfection dse poumons pour la thérapie génique contre la mucoviscidose: étude chez le porc

Open Date: 2016-01-01

Close Date: 2016-12-01

Grant: Close

Modèles de tumeurs spontanées chez l'animal pour la recherche translationnelle en cancérologie. "Towards an oncolytic vaccinia virus targeting high-grade breast carcinoma

Open Date: 2014-05-01

Close Date: 2017-04-01

Grant: Close

Evaluation in vivo d'une nouvelle formulation permettant la transfection des poumons pour la thérapie génique de la mucoviscidose: comparaison avec le composé actuellement utilisé en clinique

Open Date: 2013-01-01

Close Date: 2014-12-01

Grant: Close

Evaluation of the efficacy of oncolytic reovirus and vaccinia virus on primary mammary tumour cells: correlation with immuno-histochemical parameters.

Open Date: 2011-11-28

Close Date: 2013-12-31

Articles (10)

Year:

2024

Thousands of unique noncoding RNAs (ncRNAs) are expressed in human cells, some are tissue or cell type specific whereas others are considered as house‐keeping molecules. Studies over the last decade have modified our perception of ncRNAs from transcriptional noise to functional regulatory transcripts that influence a variety of molecular processes such as chromatin remodeling, transcription, post‐transcriptional modifications, or signal transduction. Consequently, aberrant expression of many ncRNAs plays a causative role in the initiation and progression of various diseases. Since the identification of its developmental role, the long ncRNA DNM3OS (Dynamin 3 Opposite Strand) has attracted attention of researchers in distinct fields including oncology, fibroproliferative diseases, or bone disorders. Mechanistic studies have in particular revealed the multifaceted nature of DNM3OS and its important pathogenic role in several human disorders. In this review, we summarize the current knowledge of DNM3OS functions in diseases, with an emphasis on its potential as a novel therapeutic target. This article is categorized under: RNA in Disease and Development > RNA in Disease RNA in Disease and Development > RNA in Development

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2020

Year:

2020

Collaborators (7)

Nicolas Pottier

Université de Lille

FRANCE
View details

Sophie Tartare‐Deckert

-

FRANCE
View details

Christian Dani

Université Côte d'Azur

FRANCE
View details

Antonio De la Vieja

Head of Endocrine Tumor Unit

Instituto de Salud Carlos III

SPAIN
View details

christelle cauffiez

Université de Lille

FRANCE
View details

Sophie Giorgetti-Peraldi

INSERM U1065

FRANCE
View details

kevin lebrigand

Institute of Pharmacology

FRANCE
View details
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.